Navigation Links
ViaCyte Names Michael Scott Vice President, Device Research & Development
Date:6/15/2011

SAN DIEGO, June 15, 2011 /PRNewswire/ -- ViaCyte, Inc. today announced the appointment of Michael J. Scott, Ph.D. as Vice President, Device Research and Development, reporting to John West, President and Chief Executive Officer.  In this capacity, Dr. Scott will oversee all device development and manufacturing activities, including design, engineering, and testing.  Dr. Scott will also contribute to regulatory matters in the device area and to the overall leadership and strategic direction of the Company.

"We are pleased to have Mike join ViaCyte.  He has a successful track record of leading complex device development projects, from technical innovation through clinical implementation," said Mr. West.  "We expect Mike's experience with implantable medical devices, together with our stem cell expertise, will effectively advance our combination product toward regulatory approval."

Before joining ViaCyte, Dr. Scott served in multiple managerial positions at Edwards Lifesciences, a publically traded company focused on the science of heart valves and hemodynamic monitoring.  Dr. Scott's most recent role was Senior Director of Engineering, Heart Valve Therapies, in which he managed high profile products that are currently in preclinical and clinical trial phases with commercialization expected later this year.  Dr. Scott also served as the Technical Team Leader for a bioprosthetic heart valve which is currently the best selling product of its type worldwide, generating over $100 million in annual revenue.

Dr. Scott's past experience also includes the role of Vice President of Research and Development at Orqis Medical Corporation, a venture-backed medical device startup.  Dr. Scott led Orqis to the first human use of a sophisticated implantable blood pump system for the treatment of congestive heart failure.  His broad range of responsibilities also included the oversight of system design and development, in vivo studies, and the product development pipeline.  He found the early-stage entrepreneurial environment at Orqis to be professionally rewarding and this experience will transfer to his work at ViaCyte.  Dr. Scott was educated in Canada, earning a Ph.D. in medical biophysics from the University of Western Ontario, and a B.A.Sc. and an M.A.Sc. in civil engineering from the University of Waterloo in Ontario.

"ViaCyte presents a tremendous opportunity to address an unmet need in diabetes," said Dr. Scott.  "I'm excited to be part of a team widely recognized for its scientific leadership in this area, and I look forward to applying my implantable device experience toward this worldwide medical problem."

About ViaCyte

ViaCyte is a preclinical cell therapy company focused on diabetes.  The Company's technology is based on pancreatic beta cell progenitors derived from human pluripotent stem cells.  These cells are implanted using a durable and retrievable encapsulation device.  Once implanted and matured, these cells secrete insulin in response to blood glucose levels.  ViaCyte's goal is long term insulin independence without immune suppression, and without hypoglycemia and other diabetes-related complications.

ViaCyte is a private company headquartered in San Diego, California, with additional operations in Athens, Georgia.  The Company is funded in part by the California Institute for Regenerative Medicine.

This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995.


'/>"/>
SOURCE ViaCyte, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Novocell Becomes ViaCyte, Inc., as it Accelerates Pre-Clinical Development of a Stem Cell Derived Treatment for Diabetes
2. ViaCyte, Inc., Receives Three Additional U.S. Patents, Supporting its Development of a Stem Cell Derived Treatment for Diabetes
3. PreXion, Inc. Names Visionary Industry Leader, Motoaki Saito, M.D., Ph.D. as CEO
4. Olympus Biotech Names Oliver Burckhardt to President North America
5. Delcath Names Harold C. Mapes as Executive Vice President of Global Operations
6. Savient Pharmaceuticals Names Seasoned Pharma Exec Richard Crowley EVP Biopharmaceutical Operations
7. NxStage® Names Michael Miller, Jr. President, International
8. Cetero Research Names 25-Year Industry Veteran James Dixon to Head Quality and Compliance
9. BridgePoint Medical Names Industry Veteran as Chief Executive Officer
10. Survey Sampling International Names Chris DeAngelis to Head New SSI Health
11. NAFE Names Lilly to Top 50 Companies for Executive Women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... GERMANTOWN, Maryland , May 25, ... Therawis bedient dringenden Bedarf ... QIAGEN N.V. (NASDAQ: QGEN ; ... Lizenz- und Entwicklungsvereinbarung mit Therawis Diagnostics GmbH zur ... eingegangen zu sein. Ein erstes Projekt wird die ...
(Date:5/25/2016)... Florida , May 25, 2016 ... Conference & Expo earlier this month, the numbers and ... revenues continue to climb into the billions, more research ... newly released 4th Edition State of Legal Marijuana Markets ... a cannabis-focused data-analysis firm, much of the increase in ...
(Date:5/25/2016)... 2016 ReportsnReports.com adds "Chronic ... that provides an overview on therapeutic pipeline of ... stages, therapeutics assessment by drug target, mechanism of ... type, along with latest updates, and featured news ... involved in the therapeutic development for Chronic Cough ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... ... Connor Sports, through its Connor Cares initiative, will continue to expand ... Tour that will commemorate the Indiana Fever legend’s hall-of-fame career and final WNBA ... levels of the game, Connor Sports has committed to a significantly increased focus on ...
(Date:5/26/2016)... ... May 26, 2016 , ... Cardiac arrhythmia is ... impact on long-term patient survival, reports a team of UPMC researchers in the ... in the Journal of Thoracic and Cardiovascular Surgery, provide critical information that will ...
(Date:5/26/2016)... ... May 26, 2016 , ... Catalent ... for drugs, biologics, consumer health and global clinical supply services, today announced two ... support the company’s continued investment and strategic growth plans in the Asia Pacific ...
(Date:5/26/2016)... ... ... to provide hair restoration information to the widest possible audience, Dr. Parsa Mohebi is making ... app. Dr. Mohebi, the founder of Parsa Mohebi Hair Restoration, is making all of his ... says, “The positive response to the Snapchat videos we started last month has been overwhelming. ...
(Date:5/26/2016)... ... May 26, 2016 , ... Eating Recovery Center, Washington ... opening a brand new child and adolescent residential treatment center on June 1. ... even more specialized eating disorder treatment and access to life-saving care. , To ...
Breaking Medicine News(10 mins):